ABSTRACT
The most common congenital disorder of glycosylation (CDG), phosphomannomutase 2 (PMM2)-CDG, is caused by mutations in PMM2 that limit availability of mannose precursors required for protein N-glycosylation. The disorder has no therapy and there are no models to test new treatments. We generated compound heterozygous mice with the R137H and F115L mutations in Pmm2 that correspond to the most prevalent alleles found in patients with PMM2-CDG. Many Pmm2R137H/F115L mice died prenatally, while survivors had significantly stunted growth. These animals and cells derived from them showed protein glycosylation deficiencies similar to those found in patients with PMM2-CDG. Growth-related glycoproteins insulin-like growth factor (IGF) 1, IGF binding protein-3 and acid-labile subunit, along with antithrombin III, were all deficient in Pmm2R137H/F115L mice, but their levels in heterozygous mice were comparable to wild-type (WT) littermates. These imbalances, resulting from defective glycosylation, are likely the cause of the stunted growth seen both in our model and in PMM2-CDG patients. Both Pmm2R137H/F115L mouse and PMM2-CDG patient-derived fibroblasts displayed reductions in PMM activity, guanosine diphosphate mannose, lipid-linked oligosaccharide precursor and total cellular protein glycosylation, along with hypoglycosylation of a new endogenous biomarker, glycoprotein 130 (gp130). Over-expression of WT-PMM2 in patient-derived fibroblasts rescued all these defects, showing that restoration of mutant PMM2 activity is a viable therapeutic strategy. This functional mouse model of PMM2-CDG, in vitro assays and identification of the novel gp130 biomarker all shed light on the human disease, and moreover, provide the essential tools to test potential therapeutics for this untreatable disease.
Subject(s)
Biomarkers , Congenital Disorders of Glycosylation/genetics , Cytokine Receptor gp130/genetics , Phosphotransferases (Phosphomutases)/genetics , Animals , Congenital Disorders of Glycosylation/metabolism , Congenital Disorders of Glycosylation/pathology , Cytokine Receptor gp130/biosynthesis , Disease Models, Animal , Fibroblasts/metabolism , Gene Expression Regulation , Genotype , Glycosylation , Humans , Mannose/genetics , Mannose/metabolism , Mice , MutationABSTRACT
6-Phosphogluconate dehydrogenase (6PGD) is the third enzyme in the oxidative pentose phosphate pathway (PPP). Recently, we reported that knockdown of 6PGD inhibited lung tumor growth in vitro and in a xenograft model in mice. In this study, we continued to examine the functional role of 6PGD in cancer. We show that 6PGD expression positively correlates with advancing stage of lung carcinoma. In search of functional signals related to 6PGD, we discovered that knockdown of 6PGD significantly inhibited phosphorylation of c-Met at tyrosine residues known to be critical for activity. This downregulation of c-Met phosphorylation correlated with inhibition of cell migration in vitro. Overexpression of a constitutively active c-Met specifically rescued the migration but not proliferation phenotype of 6PGD knockdown. Therefore, 6PGD appears to be required for efficient c-Met signaling and migration of tumor cells in vitro.
Subject(s)
Lung Neoplasms/metabolism , Lung Neoplasms/pathology , Lung/pathology , Phosphogluconate Dehydrogenase/genetics , Phosphogluconate Dehydrogenase/metabolism , Proto-Oncogene Proteins c-met/metabolism , Animals , Cell Line, Tumor , Cell Movement , Enzyme Activation , Gene Expression Regulation, Neoplastic , Gene Knockdown Techniques , Humans , Lung/metabolism , Lung Neoplasms/genetics , Mice , Neoplasm Staging , Phosphorylation , RNA Interference , Signal Transduction , Up-RegulationABSTRACT
6-Phosphogluconate dehydrogenase (6PGD), the third enzyme in the pentose phosphate pathway, was recently identified as a novel target in human lung cancer. In this report, we present an expression and purification scheme of recombinant human 6PGD from Escherichia coli. Using a DE3 derivative strain expressing tRNAs for seven rare codons in E. coli called Rosetta2 (DE3), a large quantity of soluble human 6PGD can be expressed with an N-terminal histidine tag and purified by a one-step purification procedure to near homogeneity without denaturants or refolding. Three to seven milligrams of purified protein could be obtained from 100 ml of culture. This recombinant human 6PGD follows classic Michaelis-Menton saturation kinetics with respect to both substrates NADP(+) and 6-phosphogluconate. The respective k(cat) and K(m) were comparable to those of 6PGDs purified from mammalian tissues. Using this purified 6PGD enzyme, we devised an endpoint colorimetric assay suitable for high-throughput screening for human 6PGD inhibitors.
Subject(s)
Histidine/genetics , Histidine/isolation & purification , Phosphogluconate Dehydrogenase/genetics , Phosphogluconate Dehydrogenase/isolation & purification , Amino Acid Sequence , Base Sequence , Cloning, Molecular , Escherichia coli/genetics , Gluconates/metabolism , Histidine/chemistry , Humans , Kinetics , Molecular Sequence Data , Phosphogluconate Dehydrogenase/chemistry , Phosphogluconate Dehydrogenase/metabolism , Plasmids/genetics , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/isolation & purification , Recombinant Proteins/metabolism , SolubilityABSTRACT
Endostatin (ES) is a fragment of collagen XVIII that possesses antiangiogenic activity. To gain insight into ES-mediated signaling, we studied the effects of ES RNA on Xenopus embryogenesis and observed developmental abnormalities consistent with impaired Wnt signaling. ES RNA blocked the axis duplication induced by beta-catenin, partially suppressed Wnt-dependent transcription, and stimulated degradation of both wild-type and "stabilized" forms of beta-catenin, the latter suggesting that ES signaling does not involve glycogen synthase kinase 3. Moreover, ES uses a pathway independent of the Siah1 protein in targeting beta-catenin for proteasome-mediated degradation. ES failed to suppress the effects of T cell-specific factor (TCF)-VP16 (TVP), a constitutive downstream transcriptional activator that acts independently of beta-catenin. Importantly, these data were replicated in endothelial cells and also in the DLD-1 colon carcinoma cells with the mutated adenomatous polyposis coli protein. Finally, suppression of endothelial cell migration and inhibition of cell cycle by ES were reversed by TVP. Though high levels of ES were used in both the Xenopus and endothelial cell studies and the effects on beta-catenin signaling were modest, these data argue that at pharmacological concentrations ES may impinge on Wnt signaling and promote beta-catenin degradation.
Subject(s)
Angiogenesis Inhibitors/metabolism , Collagen/metabolism , Endothelium, Vascular/metabolism , Gene Expression Regulation, Developmental/physiology , Neovascularization, Pathologic/metabolism , Oocytes/metabolism , Peptide Fragments/metabolism , Proto-Oncogene Proteins/metabolism , Signal Transduction/genetics , Xenopus laevis/abnormalities , Zebrafish Proteins , Angiogenesis Inhibitors/genetics , Animals , Body Patterning/genetics , Cell Movement/genetics , Collagen/genetics , Collagen Type XVIII , Cytoskeletal Proteins/genetics , Cytoskeletal Proteins/metabolism , Endostatins , Endothelium, Vascular/cytology , Female , Growth Substances/pharmacology , Heparan Sulfate Proteoglycans/genetics , Heparan Sulfate Proteoglycans/metabolism , Humans , Mutation/physiology , Neovascularization, Pathologic/drug therapy , Neovascularization, Pathologic/genetics , Nuclear Proteins/genetics , Nuclear Proteins/metabolism , Oocytes/cytology , Peptide Fragments/genetics , Protein Structure, Tertiary/genetics , Proto-Oncogene Proteins/genetics , RNA, Messenger/genetics , RNA, Messenger/metabolism , S Phase/drug effects , S Phase/physiology , Trans-Activators/genetics , Trans-Activators/metabolism , Tumor Cells, Cultured , Ubiquitin-Protein Ligases , Wnt Proteins , Xenopus Proteins , Xenopus laevis/genetics , Xenopus laevis/metabolism , beta CateninABSTRACT
Thrombin potently induces endothelial inflammation. One of the responses is upregulation of adhesion molecules such as ICAM-1, resulting in enhanced leukocyte attachment to the endothelium. In this report, we examine the contribution of EphA2 in thrombin-induced expression of ICAM-1 in human umbilical vein endothelial cells (HUVECs). We showed that thrombin transiently induced tyrosine- phosphorylation of EphA2 in a Src-kinase dependent manner. This transactivation was mediated through PAR-1, because a PAR-1 specific agonistic peptide also transactivated EphA2. Expression knockdown of endogenous EphA2 by siRNAs blocked ICAM-1 upregulation and leukocyte/endothelium attachment induced by thrombin. Overexpression of exogenous mouse EphA2 rescued both ICAM-1 expression and leukocyte attachment induced by thrombin in endogenous EphA2-knockdown HUVECs. Mechanistically, we showed EphA2 knockdown suppressed thrombin-induced serine 536 phosphorylation of NFkappaB, an event critical of ICAM-1 transcriptional upregulation. Collectively, our results strongly suggest EphA2 is a necessary component for thrombin-induced ICAM-1 upregulation.
Subject(s)
Endothelial Cells/metabolism , Gene Expression Regulation/drug effects , Intercellular Adhesion Molecule-1/genetics , Receptor, EphA2/physiology , Thrombin/pharmacology , Cells, Cultured , Humans , Monocytes/physiology , NF-kappa B/metabolism , Phosphorylation , Receptor, PAR-1/physiology , Tyrosine/metabolism , Up-Regulation , src-Family Kinases/physiologyABSTRACT
Tie-1 is an endothelial specific cell surface protein whose biology remains poorly understood. Using an overexpression system in vitro, we examined whether Tie-1 activity in endothelial cells in vitro would elicit a proinflammatory response. We found that when overexpressed in endothelial cells in vitro, Tie-1 is tyrosine-phosphorylated. We also showed that Tie-1 upregulates VCAM-1, E-selectin, and ICAM-1, partly through a p38-dependent mechanism. Interestingly, upregulation of VCAM-1 and E-selectin by Tie-1 is significantly higher in human aortic endothelial cells than in human umbilical vein endothelial cells. Additionally, attachment of cells of monocytic lineage to endothelial cells is also enhanced by Tie-1 expression. Collectively, our data show that Tie-1 has a proinflammatory property and may play a role in the endothelial inflammatory diseases such as atherosclerosis.
Subject(s)
Cell Adhesion , E-Selectin/metabolism , Endothelium, Vascular/enzymology , Intercellular Adhesion Molecule-1/metabolism , Receptor, TIE-1/metabolism , Vascular Cell Adhesion Molecule-1/metabolism , Animals , Aorta/cytology , Aorta/metabolism , E-Selectin/genetics , Endothelium, Vascular/cytology , Green Fluorescent Proteins/genetics , Humans , Intercellular Adhesion Molecule-1/genetics , Mice , Monocytes/physiology , Phosphorylation , Receptor, TIE-1/genetics , Tyrosine/metabolism , Up-Regulation , Vascular Cell Adhesion Molecule-1/genetics , p38 Mitogen-Activated Protein Kinases/genetics , p38 Mitogen-Activated Protein Kinases/metabolismABSTRACT
A critical role for Tie1, an orphan endothelial receptor, in blood vessel morphogenesis has emerged from mutant mouse studies. Moreover, it was recently demonstrated that certain angiopoietin (Ang) family members can activate Tie1. We report here that Ang1 induces Tie1 phosphorylation in endothelial cells. Tie1 phosphorylation was, however, Tie2 dependent because 1) Ang1 failed to induce Tie1 phosphorylation when Tie2 was down-regulated in endothelial cells; 2) Tie1 phosphorylation was induced in the absence of Ang1 by either a constitutively active form of Tie2 or a Tie2 agonistic antibody; 3) in HEK 293 cells Ang1 phosphorylated a form of Tie1 without kinase activity when coexpressed with Tie2, and Ang1 failed to phosphorylate Tie1 when coexpressed with kinase-defective Tie2. Ang1-mediated AKT and 42/44MAPK phosphorylation is predominantly Tie2 mediated, and Tie1 down-regulates this pathway. Finally, based on a battery of in vitro and in vivo data, we show that a main role for Tie1 is to modulate blood vessel morphogenesis by virtue of its ability to down-regulate Tie2-driven signaling and endothelial survival. Our new observations help to explain why Tie1 null embryos have increased capillary densities in several organ systems. The experiments also constitute a paradigm for how endothelial integrity is fine-tuned by the interplay between closely related receptors by a single growth factor.
Subject(s)
Cell Survival , Endothelial Cells/metabolism , Receptor, TIE-1/metabolism , Receptor, TIE-2/metabolism , Signal Transduction/physiology , Angiopoietin-1/metabolism , Animals , Apoptosis , Blood Vessels/anatomy & histology , Blood Vessels/growth & development , Caspase 3/metabolism , Cell Line , Embryo, Mammalian/anatomy & histology , Embryo, Mammalian/pathology , Embryo, Mammalian/physiology , Endothelial Cells/cytology , Enzyme Activation , Female , Humans , In Situ Nick-End Labeling , Male , Mice , Neovascularization, Physiologic , Phosphorylation , Proto-Oncogene Proteins c-akt/metabolism , RNA, Small Interfering/metabolism , Receptor, TIE-1/genetics , Receptor, TIE-2/genetics , Tissue Culture TechniquesABSTRACT
The vasculature consists of endothelial cells (ECs) lined by pericyte/vascular smooth muscle cells (vSMCs). Pericyte/vSMCs provide support to the mature vasculature but are also essential for normal blood vessel development. To determine how pericyte-EC communication influences vascular development, we used the well-established in vitro model of TGFbeta-stimulated differentiation of 10T1/2 cells into pericyte/vSMCs. Microarray analysis was performed to identify genes that were differentially expressed by induced vs. uninduced 10T1/2 cells. We discovered that these cells show an angiogenic program of gene expression, with up-regulation of several genes previously implicated in angiogenesis, including VEGF, IL-6, VEGF-C, HB-EGF, CTGF, tenascin C, integrin alpha5, and Eph receptor A2. Up-regulation of some genes was validated by Western blots and immunocytochemistry. We also examined the functional significance of these gene expression changes. VEGF and IL-6 alone and in combination were important in 10T1/2 cell differentiation. Furthermore, we used a coculture system of 10T1/2 and human umbilical vein ECs (HUVECs), resulting in the formation of cordlike structures by the HUVECs. This cordlike structure formation was disrupted when neutralizing antibodies to VEGF or IL-6 were added to the coculture system. The results of these studies show that factors produced by pericytes may be responsible for recruiting ECs and promoting angiogenesis. Therefore, a further understanding of the genes involved in pericyte differentiation could provide a novel approach for developing anti-angiogenic therapies.
Subject(s)
Cell Differentiation/genetics , Gene Expression Profiling/methods , Gene Expression Regulation/genetics , Microarray Analysis/methods , Neovascularization, Physiologic/genetics , Pericytes/cytology , Animals , Cell Line , Coculture Techniques , Embryo, Mammalian/cytology , Genes/physiology , Humans , Mice , Mice, Inbred C3H , Multipotent Stem Cells/chemistry , Multipotent Stem Cells/cytology , Multipotent Stem Cells/metabolism , Pericytes/chemistry , Pericytes/metabolism , Umbilical Veins/chemistry , Umbilical Veins/cytology , Umbilical Veins/metabolismABSTRACT
BACKGROUND: Many antiangiogenic molecules are proteolytically cleaved from larger plasma proteins. For example, plasminogen activators cleave plasminogen into plasmin, and plasmin is converted into angiostatin in the presence of sulfhydryl donors. We thus investigated whether the antiangiogenic activity in plasma could be increased by treatment with recombinant tissue plasminogen activator (rt-PA) and the sulfhydryl donor captopril. METHODS: Human plasma was treated with rt-PA (10 micro g/mL) and/or captopril (1 micro M). Angiogenesis was measured in vitro by human endothelial cell tube formation and endothelial cell proliferation and in vivo in mice with the Matrigel plug assay. Angiostatin was removed from treated plasma by affinity chromatography, immunoprecipitation, or ion-exchange chromatography, and the antiangiogenic activity of the depleted plasma was assessed by tube formation. Three cancer patients were treated with rt-PA and captopril, and their pretreatment and post-treatment plasmas were tested for antiangiogenic activity in vitro. RESULTS: Angiogenesis in vitro was stimulated by untreated plasma and inhibited by plasma that had been treated with rt-PA and captopril but was not affected by treatment with rt-PA and/or captopril alone. In vivo angiogenesis in Matrigel plugs was substantially lower in mice treated with rt-PA and captopril than in untreated control mice. Antiangiogenic activity in treated plasma was largely retained after angiostatin was removed: treated plasma inhibited angiogenesis by 64.3% (95% confidence interval [CI] = 46.4% to 82.2%), relative to untreated plasma, and treated plasma depleted of angiostatin by affinity chromatography or immunoprecipitation inhibited angiogenesis by 65.1% (95% CI = 53.8% to 76.4%) or 63.7% (95% CI = 50.9% to 76.5%), respectively. Antiangiogenic activity of plasma from three cancer patients was higher after treatment with rt-PA and captopril than before such treatment. CONCLUSION: Treatment with rt-PA and captopril induced antiangiogenic activity in vitro and in vivo that appears to be independent of angiostatin.
Subject(s)
Angiogenesis Inhibitors/pharmacology , Captopril/pharmacology , Neovascularization, Pathologic/drug therapy , Peptide Fragments/pharmacology , Plasma/drug effects , Plasminogen Activators/pharmacology , Plasminogen/pharmacology , Angiogenesis Inhibitors/administration & dosage , Angiostatins , Animals , Captopril/administration & dosage , Cell Culture Techniques , Chromatography , Collagen , Drug Combinations , Electrophoresis, Polyacrylamide Gel , Endothelium, Vascular/drug effects , Female , Humans , Laminin , Mice , Middle Aged , Neovascularization, Pathologic/metabolism , Peptide Fragments/administration & dosage , Plasma/metabolism , Plasminogen/administration & dosage , Plasminogen Activators/administration & dosage , Precipitin Tests , Proteoglycans , Recombinant Proteins/pharmacologyABSTRACT
We show that knockdown of 6-phosphogluconate dehydrogenase (6PGD) of the pentose phosphate pathway (PPP) inhibits growth of lung cancer cells by senescence induction. This inhibition is not due to a defect in the oxidative PPP per se. NADPH and ribose phosphate production are normal in 6PGD knockdown cells and shutdown of PPP by knockdown of glucose-6-phosphate dehydrogenase (G6PD) has little effect on cell growth. Moreover, 6PGD knockdown cells can proliferate when the PPP is bypassed by using fructose instead of glucose in medium. Significantly, G6PD knockdown rescues proliferation of cells lacking 6PGD, suggesting an accumulation of growth inhibitory glucose metabolics in cells lacking 6PGD. Therefore, 6PGD inhibition may provide a novel strategy to treat glycolyic tumors such as lung cancer.
Subject(s)
Gene Expression Regulation, Neoplastic , Glucose/metabolism , Lung Neoplasms/metabolism , Phosphogluconate Dehydrogenase/genetics , Animals , Cell Proliferation , Cellular Senescence , Glycolysis , Humans , Lung Neoplasms/genetics , Mice , Mice, Nude , Oxidative Stress , Oxygen/chemistry , Oxygen Consumption , Pentose Phosphate Pathway , Phosphogluconate Dehydrogenase/metabolism , Tumor Suppressor Protein p53/metabolismABSTRACT
Tie-1 is an endothelial specific receptor tyrosine kinase that is upregulated in diseases such as atherosclerosis and rheumatoid arthritis. We recently demonstrated that Tie-1 induced a proinflammatory response when overexpressed in endothelial cells. Here, we used a complementary approach and suppressed endogenous Tie-1 expression in endothelial cells to examine its function by microarray analysis. Tie-1 appeared to govern expression of many genes involved in inflammation. Expression knockdown of Tie-1 significantly reduced endothelial conditioned medium ability to stimulate MCP-1 production in U937 cells. Collectively, our results support the notion that Tie-1 has an inflammatory function in endothelial cells.
Subject(s)
Endothelial Cells/drug effects , Gene Expression Regulation/drug effects , Inflammation/genetics , RNA, Small Interfering/pharmacology , Receptor, TIE-1/antagonists & inhibitors , Cells, Cultured , Endothelial Cells/metabolism , Gene Expression Profiling , Genome, Human , Humans , Monocytes/drug effects , Monocytes/physiology , Oligonucleotide Array Sequence Analysis , RNA Interference/physiology , Receptor, TIE-1/genetics , Receptor, TIE-1/metabolism , Receptor, TIE-1/physiology , U937 CellsABSTRACT
Angiopoietin-1 (Ang-1), a ligand of the endothelium-specific receptor Tie-2, inhibits permeability in the mature vasculature, but the mechanism remains unknown. Here we show that Ang-1 signals Rho family GTPases to organize the cytoskeleton into a junction-fortifying arrangement that enhances the permeability barrier function of the endothelium. Ang-1 phosphorylates Tie-2 and its downstream effector phosphatidylinositol 3-kinase. This induces activation of one endogenous GTPase, Rac1, and inhibition of another, RhoA. Loss of either part of this dual effect abrogates the cytoskeletal and anti-permeability actions of Ang-1, suggesting that coordinated GTPase regulation is necessary for the vessel-sealing effects of Ang-1. p190 RhoGAP, a GTPase regulatory protein, provides this coordinating function as it is phosphorylated by Ang-1 treatment, requires Rac1 activation, and is necessary for RhoA inhibition. Ang-1 prevents the cytoskeletal and pro-permeability effects of endotoxin but requires p190 RhoGAP to do so. Treatment with p190 RhoGAP small interfering RNA completely abolishes the ability of Ang-1 to rescue endotoxemia-induced pulmonary vascular leak and inflammation in mice. We conclude that Ang-1 prevents vascular permeability by regulating the endothelial cytoskeleton through coordinated and opposite effects on the Rho GTPases Rac1 and RhoA. By linking Rac1 activation and RhoA inhibition, p190 RhoGAP is critical to the protective effects of Ang-1 against endotoxin. These results provide mechanistic evidence that targeting the endothelium through Tie-2 may offer specific therapeutic strategies in life-threatening endotoxemic conditions such as sepsis and acute respiratory distress syndrome.
Subject(s)
Angiopoietin-1/metabolism , Angiopoietin-1/physiology , Capillary Permeability , GTPase-Activating Proteins/metabolism , rac1 GTP-Binding Protein/metabolism , rhoA GTP-Binding Protein/antagonists & inhibitors , Animals , Cells, Cultured , Endothelium, Vascular/cytology , Humans , Mice , Phosphorylation , Receptor, TIE-2/metabolismABSTRACT
In this report, we use zebrafish as a model system to understand the importance of CD146 in vascular development. Endothelial-specific expression of CD146 was verified by whole-mount in situ hybridization. Suppression of CD146 protein expression by antisense morpholino oligonucleotides (MO) resulted in poorly developed intersomitic vessels (ISVs). In CD146 morphants, we observed a lack of blood flow through the ISV region, despite that fluorescence microangiography showed that the ISVs were present. This finding suggests that the lumens of the developing ISVs may be too narrow for proper circulation. Additionally, remodeling of the caudal vein plexus into functional vascular tubes appeared to be affected. Suppression of CD146 protein expression resulted in a circulation shunt that caused the circulation to by-pass part of the caudal artery/vein system. The same vascular defects were recapitulated by using a second morpholino oligonucleotide. This morphant expressed a truncated CD146 protein with amino acids V32 to T57 at the N terminus deleted in an in-frame manner. This region, therefore, is likely to contain elements critical for CD146 function. This study provides the first in vivo functional assessment of CD146 in embryonic development by showing that knockdown of CD146 protein expression severely hinders vascular development in zebrafish.
Subject(s)
Antigens, CD/physiology , Blood Vessels/embryology , Endothelium, Vascular/embryology , Gene Expression Regulation, Developmental , Neural Cell Adhesion Molecules/physiology , Amino Acid Sequence , Angiography , Animals , Antigens, CD/metabolism , Base Sequence , CD146 Antigen , Cloning, Molecular , DNA, Complementary/metabolism , In Situ Hybridization , Microscopy, Fluorescence , Molecular Sequence Data , Neural Cell Adhesion Molecules/metabolism , Oligonucleotides/chemistry , Protein Structure, Tertiary , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Sequence Homology, Amino Acid , Time Factors , ZebrafishABSTRACT
Using protein chromatography, we purified and identified human prothrombin from human plasma as antiangiogenic. Prothrombin significantly inhibited endothelial cell tube formation in vitro at 10 microg/ml. Importantly, it also inhibited bFGF-induced angiogenesis in Matrigel-plug assays performed in mice. The proteolytic activity of thrombin appeared to be critical for the antiangiogenic activity of prothrombin. For example, thrombin exhibited inhibitory effects on endothelial cell tube formation in vitro at 10 U/ml. Addition of lepirudin, a specific inhibitor of thrombin, completely blocked prothrombin's and thrombin's antiangiogenic effects in vitro. We also assessed the importance of thrombin receptors in angiogenesis. Using small peptides that activate different protease-activated receptors (PARs), we showed that activation of PAR-1 led to inhibition of endothelial cell tube formation in vitro and bFGF-induced angiogenesis in vivo. Collectively, our data suggest that thrombin's proteolytic activity can be antiangiogenic.
Subject(s)
Angiogenesis Inhibitors/pharmacology , Thrombin/pharmacology , Thrombin/physiology , Cell Division , Cells, Cultured , Chromatography , Chromatography, Ion Exchange , Collagen/pharmacology , Dose-Response Relationship, Drug , Drug Combinations , Electrophoresis, Polyacrylamide Gel , Endopeptidases/metabolism , Endothelial Cells/metabolism , Endothelium, Vascular/cytology , Humans , Laminin/pharmacology , Neovascularization, Pathologic , Peptides/chemistry , Phorbol Esters/metabolism , Proteoglycans/pharmacology , Prothrombin/metabolism , Receptor, PAR-1/metabolism , Receptors, Proteinase-Activated/metabolism , Thrombin/metabolism , Umbilical Veins/cytologyABSTRACT
Endostatin, a type XVIII collagen fragment, is a potent antiangiogenic molecule that inhibits endothelial cell migration, promotes apoptosis, and induces cell cycle arrest in vitro. We have investigated the mechanism by which endostatin causes G(1) arrest in endothelial cells. Endostatin decreased the hyperphosphorylated retinoblastoma gene product and down-regulated cyclin D1 mRNA and protein. Importantly, endostatin was unable to arrest cyclin D1 overexpressing endothelial cells, suggesting that cyclin D1 is a critical target for endostatin action. Next, we analyzed cyclin D1 promoter activity in endothelial cells and found that endostatin down-regulated the cyclin D1 promoter. Using a series of deletion and mutant promoter constructs, we identified the LEF1 site in the cyclin D1 promoter as essential for the inhibitory effect of endostatin. Finally, we showed that endostatin can repress cyclin D1 promoter activity in cells over-expressing beta-catenin but not in cells over-expressing a transcriptional activator that functions through the LEF1 site and is insensitive to beta-catenin. Collectively, our data pointed to a role for cyclin D1, and in particular, transcription through the LEF1 site as critical for endostatin action in vitro and suggest that beta-catenin is a target for endostatin.